Investors Are Fleeing These 10 Stocks

US markets fell further on Tuesday as investors trimmed positions ahead of Nvidia Corp.’s much-anticipated earnings report, which came out shortly after the market closed. The Dow Jones fell the most, down 1.63%, followed by the S&P 500, which fell 1.03%. The tech-heavy Nasdaq decreased 0.74%.

Amid the decline, 10 stocks fell the most, with some hitting record lows during the session. In this article, we identify their names and detail the reasons behind their drop.

To come up with the list, we exclusively considered the stocks with more than $1 billion in market capitalization and 5 million shares in trading volume.

Photo by Tima Miroshnichenko on Pexels

10. Enphase Energy Inc. (NASDAQ:ENPH)

Enphase Energy fell to a new 52-week low on Tuesday, mirroring a broader market decline, while investors repositioned portfolios ahead of key business updates this week.

The stock dropped to its lowest price of $23.03 in intraday trading and ended down by 7.58 percent at $23.06 apiece.

In an updated report, Enphase Energy Inc. (NASDAQ:ENPH) said that its co-founder and chief product officer, Raghu Belur, is set to present at the RE+ 2026 conference in Las Vegas on Wednesday, November 18, where investors are also expected to watch for the company’s updated outlook for the rest of the year.

Additionally, the company will showcase a range of current and new products for homes and businesses, including its solid-state transformer built for artificial intelligence data centers; a 5th-generation battery for higher energy density in a space-saving stackable design; a bidirectional electric vehicle charger with a complete vehicle-to-home and vehicle-to-grid solution; and its first commercial battery capable of delivering 80 kWh and up to 40 kVA in a single enclosure.

In other news, Enphase Energy Inc. dropped its net income in the third quarter of the year by 65 percent to only $23.39 million from $66.6 million in the same period last year.

Revenues dropped by 28 percent to $293.3 million from $410 million year-on-year.

9. JD.com Inc. (NASDAQ:JD)

JD.com saw its share price decline by 7.66 percent on Tuesday to finish at $25.43 apiece, as investors sold off positions after missing analyst estimates for the first time in eight consecutive quarters.

In an updated report, JD.com Inc. (NASDAQ:JD) said that its net income attributable to shareholders climbed by 22.6 percent to RMB6.5 billion from RMB5.3 billion in the same period last year, while net revenues jumped by 3.5 percent to RMB309.6 billion from RMB299 billion year-on-year.

The retail segment remained the largest contributor at RMB257.97 billion, marking growth of 2.9 percent from the RMB250.58 billion in the same comparable period.

Operating income totaled RMB5.2 billion, as compared with an operating loss of RMB1.1 billion a year earlier.

“We delivered solid results in the third quarter, returning to positive revenue growth while accelerating profit growth. This performance was underpinned by the resilience of JD Retail and continued loss reduction in new businesses,” JD.com Inc. CEO Sandy Xu said.

“We also expanded our user base in the quarter alongside a notable year-on-year reduction in marketing expenses, reflecting our focus on operating efficiency. Beyond the healthy fundamentals of our existing operations, we were encouraged by the successful closing of the Ceconomy acquisition, which marks an important step forward in our global retail and logistics expansion. Overall, as we deepen our roots in existing markets while extending our international reach, we are establishing a solid foundation for long-term, high-quality growth,” she noted.

8. Salesforce Inc. (NYSE:CRM)

Salesforce fell by 9.45 percent on Tuesday to end at $194.52 apiece, as investor focus shifted to reports of a new round of job cuts, shunning its newly clinched partnership with Microsoft Corp.

A report by Business Insider citing internal letters to employees said that Salesforce Inc. (NYSE:CRM) kicked off another round of workforce reduction as part of its restructuring activity amid mounting scrutiny over the impact of AI on traditional software businesses. The extent of the latest job cuts has not been identified.

The initiative followed the first job cut in June, under which 86 positions across sales, general administration, technology, and product functions in California have been axed.

In a separate development, Salesforce Inc. joined forces with Microsoft for the launch of Copilotforce, a new partnership that helps employees get more done in the tools they already use by bringing Salesforce customer context, business processes, and actions into Microsoft Copilot and other AI-powered productivity experiences.

The partnership integrates Microsoft Copilot, Microsoft Teams and Microsoft Fabric, including Salesforce in Copilot, a plugin available in public preview with 38+ prebuilt sales skills. These capabilities help businesses move faster, reduce manual work and get more value from their existing technology investments—while maintaining the security, governance and permissions they already rely on.

7. Summit Therapeutics Inc. (NASDAQ:SMMT)

Summit Therapeutics extended its losing streak to a 5th consecutive day on Tuesday to hit a new 52-week low, as investors resumed selling positions after the Food and Drug Administration (FDA) declined its biologics license application for its lung cancer treatment.

In intraday trading, the stock dropped to a new record low of $10.53 before ending the day down 9.73 percent at $10.67 apiece.

In a regulatory filing on Monday, Summit Therapeutics Inc. (NASDAQ:SMMT) said that the FDA rejected its BLA after determining that substantial evidence of effectiveness was not established amid the absence of a statistically significant improvement in enrolled patients’ overall survival.

Additionally, the FDA indicated that data on progression-free survival (PFS) without any improvement in overall survival do not support a positive benefit-risk profile.

The BLA was based on Summit Therapeutics Inc.’s data from its double-blind Phase 3 clinical trial, which aimed to study Ivonescimab in combination with chemotherapy, where PFS—its primary endpoint—was met.

The study found that Ivonescimab combined with chemotherapy was well-tolerated with no new safety signals and comparable rates of discontinuation and death.

The study found that Ivonescimab combined with chemotherapy was well-tolerated with no new safety signals and comparable rates of discontinuation and death.

However, 16 patients in the Ivonescimab group and 11 patients in the placebo group discontinued due to adverse effects.

Nine patients died, including four from the Ivonescimab plus chemotherapy arm group, and five in the chemotherapy alone.

“We are disappointed for patients and their families awaiting additional treatment options in this setting,” Chairman and CEO Robert Duggan said.

6. Uniti Group Inc. (NASDAQ:UNIT)

Uniti Group saw its share price fall by 10.86 percent on Tuesday to finish at $4.27 apiece, as investors disposed of its shares amid the lack of fresh catalysts to support buying appetite.

Last week, Uniti Group Inc. (NASDAQ:UNIT) announced the successful trial of an industry-first 800 Gigabit Ethernet (800GE) service in Chicago, Illinois, and Lexington, Kentucky, demonstrated using a Nokia 1830 Global Express (GX) solution.

It expects to make the service available to customers in the first quarter of 2027.

Unlike other available 800GE client interfaces that rely on multiple fiber pairs, the trial validated that Uniti Group Inc.’s (NASDAQ:UNIT) system is able to provide the complete 800G customer handoff over a single fiber pair.

“Our customers are looking for more capacity, but they also want the experience of connecting to that capacity to be as simple and efficient as possible,” said Greg Ortyl, executive vice president and president of strategic accounts for Uniti Wholesale.

“By demonstrating an 800G service with a single fiber pair handoff, we are simplifying the customer connection while giving businesses a straightforward path to the next generation of high-capacity connectivity,” he added.

5. Bitdeer Technologies Group (NASDAQ:BTDR)

Bitdeer Technologies extended its losing streak to a 4th consecutive day on Tuesday, shedding 11.01 percent to close at $4 apiece, as investor sentiment was weighed down by its close links to US Commerce Secretary Howard Lutnick, who is facing allegations of easing AI rules to the benefit of his family’s business.

The New York Times reported on Tuesday that Lutnick—who founded financial services firm Cantor Fitzgerald, now run by his sons since he joined President Donald Trump’s cabinet—owns a new data center in Malaysia that is set to open next year.

Owned by Bitdeer Technologies Group (NASDAQ:BTDR), the data center was poised to sell Nvidia Corp.’s chips to a Chinese tech giant, sidestepping US rules that ban the sale of advanced US chips to China.

It can be recalled that Cantor Fitzgerald served as a sales agent for Bitdeer Technologies Group’s $1 billion equity offering, and also assisted the listed firm with arranging a stock offering of up to $250 million. Cantor Fitzgerald also has business ties to several data center companies in Southeast Asia.

Apart from links to Lutnick, the drop in shares of Bitdeer Technologies Group may have also been dampened by Bitcoin’s 1.14 percent fall to the $64,000 territory amid lingering uncertainties about the artificial intelligence buildout.

4. Icahn Enterprises Ltd. (NASDAQ:IEP)

Icahn Enterprises fell by 11.39 percent on Tuesday to close at $3.19 apiece, as investors disposed of its shares following the ex-date for its next dividend payment.

It can be recalled that the company’s board of directors approved the distribution of $0.50 in dividends to all depositary unit holders of November 16 record, payable on December 23. The dividends form part of Icahn Enterprises LP’s (NASDAQ:IEP) quarterly dividends.

The distribution announcement followed Icahn Enterprises LP’s (NASDAQ:IEP) earnings results in the third quarter of the year, where it swung to an attributable net loss of $225 million from a $287 million net income in the same period last year amid refining hedges in the investment funds attributable to the company.

Revenues, on the other hand, increased by 16 percent to $3.17 billion from $2.7 billion year-on-year, with net sales contributing to the bulk at $3.549 billion, or 53 percent higher than $2.3 billion year-on-year.

However, the higher net sales were offset by losses from investment activities, at $779 million versus $48 million in the same comparable period.

Adjusted EBITDA attributable to the company ended at a loss of $214 million, as compared with a $75 million adjusted EBITDA year-on-year.

3. Nextpower Inc. (NASDAQ:NXT)

Nextpower saw its share prices fall by 12.13 percent on Tuesday to finish at $78.48 apiece, as investors took path from two investment firms’ lower price targets for its stock.

In separate market notes on the same day, JPMorgan and BMO Capital both reduced their price targets for the stock, while maintaining overweight and outperform ratings.

JPMorgan now prices the company at $133 versus $134 previously, while BMO Capital dropped its target to $108 from $114 earlier.

For its part, BMO Capital said that while Nextpower Inc. (NASDAQ:NXT) outlined a rosier growth opportunity for fiscal year 2030, its 2028 margin commentary effectively lowered near-term profit expectations.

It said that another year of investment could delay operating leverage, which could materialize only in fiscal 2029 and 2030.

BMO Capital said that Nextpower Inc.’s broader product portfolio and higher fiscal 2030 earnings forecasts support its strategy to capture a larger share of customer spending, although the financial benefits are taking longer than anticipated.

2. Shoals Technologies Group Inc. (NASDAQ:SHLS)

Shoals Technologies dropped for a second day on Tuesday, slashing 12.22 percent to finish at $7.04 apiece, as investor sentiment was dampened by a downgrade from UBS amid uncertainties surrounding its merger with Array Technologies.

In a market note on the same day, the investment firm downgraded the stock to neutral from buy, as well as its price target to $9 from $12, saying that its proposed merger with Array cannot be considered a finished product, but a move that is overall positive.

UBS said that it expects further mergers and acquisitions into tangential product categories likely after the closing.

The investment firm raised its cumulative adjusted EBITDA estimates by 5 percent between 2026 and 2028 to reflect Shoals Technologies Group Inc.’s (NASDAQ:SHLS) results in the third quarter of the year and higher gross margins driven by the consolidation of manufacturing activities at the company’s new facility.

In the third quarter of the year, Shoals Technologies Group Inc. said that its net income surged by 50 percent in the third quarter of the year to $17.87 million from $11.88 million in the same period last year.

Revenues jumped by 43.8 percent to $195.3 million from $135.8 million year-on-year.

1. Omeros Corporation (NASDAQ:OMER)

Omeros Corp. (NASDAQ:OMER) fell by 16.55 percent on Tuesday to close at $13.92 apiece, after incurring wider losses in the third quarter of the year.

In an updated report, the company said that its net loss fell by 85 percent to $57.3 million from $30.9 million in the same period last year, dragged down by a non-cash loss of $62 million primarily related to mark-to-market adjustments of a derivative associated with its unsecured convertible notes due 2029.

Meanwhile, it incurred $35.9 million in product sales, thanks to the strong uptake of Yartemlea—the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy.

“Yartemlea sales continued to grow during the third quarter, delivering consecutive quarters of positive operating cash flow,” Omeros Corporation Chairman and CEO Gregory Demopulos said.

“As expected, 340B participation increased, reflecting substantial expansion of our customer base and increased outpatient use of Yartemlea. That momentum has continued into the fourth quarter, with Yartemlea revenues continuing to grow,” he noted.

In other news, Omeros Corporation announced last month that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) thumbed down its marketing authorization application for narsoplimab, under the brand name Yartemlea, for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) following re-examination of its original negative opinion adopted in June 2026.

An eight-member ad hoc expert group (AHEG) consisting of hematologists, statisticians, and transplant physicians, together with two patient representatives, was convened by CHMP as part of the re-examination process.

“We are deeply disappointed in the re-examination process and outcome…We believe that our Yartemlea efficacy and safety data, FDA’s recent approval with a broad indication for both adults and children, a decade of compassionate use requests by European transplant physicians for their TA-TMA patients, and the rapid US commercial adoption speak clearly to the favorable benefit-risk profile of the drug,” he noted.

READ NEXT: Forget Nvidia: 10 Stocks Wall Street is Betting on Right Now and Buy Alert: 10 Stocks Analysts Upgraded on Friday

Follow Insider Monkey on Google News.